COMMUNIQUÉS West-GlobeNewswire

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
14/09/2026
Company to host a virtual event today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential [...]
As New York Fashion Week Kicks Off, Kraig Labs Advances Spider Silk for Fashion's Next Generation of Designers
14/09/2026
Fashion industry shift puts new focus on bio-based and innovative textiles as Kraig Labs scales recombinant spider silk for potential luxury and performance applications ANN ARBOR, Mich., Sept. 14, 2026 (GLOBE NEWSWIRE [...]
NANOBIOTIX annonce les résultats complets de la phase 1 pour JNJ-1900 (NBTXR3) dans le cancer du poumon non à petites cellules inopérable et récurrent
14/09/2026
L’ensemble des 24 patients a été traité sans toxicité limitant la dose, sans événement indésirable de grade 3 ou supérieur liés à JNJ-1900 (NBTXR3) ou à la procédure d’injection, et l’injection intratumorale a été jugée [...]
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
14/09/2026
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One- [...]
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
14/09/2026
LONDON and PHILADELPHIA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, today [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
14/09/2026
COPENHAGEN, Denmark, September 14, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Cellectis annonce sa transformation stratégique en société d'édition du génome in vivo
14/09/2026
Cellectis fait progresser ses deux programmes in vivo phares, .HEAL-101 et .HEAL-201 dans les dyslipidémies sévères, avec des données préliminaires de phase 1 attendues respectivement au second semestre 2027 et au [...]
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
14/09/2026
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectively Transformation supported by continuing existing [...]
Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture
14/09/2026
Bagsværd, Denmark, 14 September 2026 – Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name, and by updating its culture [...]
Initiation of Novonesis’ share buyback program
14/09/2026
Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, [...]
Bio Usawa and Axmed Partner to Expand Access to Affordable Biologic Medicines Across Africa
14/09/2026
Strategic collaboration combines African biologics capabilities with technology-enabled procurement, with an initial focus on retinal diseases KIGALI, Rwanda and BASEL, Switzerland, Sept. 14, 2026 (GLOBE NEWSWIRE) -- [...]
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
14/09/2026
Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current [...]
Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
14/09/2026
Amivantamab plus chemotherapy demonstrates durable benefit with a differentiated approach that dual targets EGFR and MET 1 Median overall survival reached 34.3 months with the amivantamab-based regimen, the longest [...]
Beverly Wilshire Aesthetics Beverly Hills Medical Spa Announces Global Rebrand, Expanding Botox, Dermal Fillers, and Morpheus8 Services
14/09/2026
BEVERLY HILLS, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beverly Wilshire Aesthetics Medical Spa Beverly Hills is a leading full-service medical spa serving patients throughout Beverly Hills and the Los Angeles [...]
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
14/09/2026
Allschwil, Switzerland, September 14, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
MemoHoney Launch Advanced Brain Memory Support Capsules 2026 in USA: Read Memohoney Supplement Facts, Benefits and Ingredients Highlights.
13/09/2026
MemoHoney 2026 Announces a natural formula in the USA, designed to support brain health, memory and focus. Explore Memo Honey supplement facts, ingredients and key benefits. New York, Sept. 13, 2026 (GLOBE NEWSWIRE) -- [...]
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
13/09/2026
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving [...]
Zenbody RX Launches Telehealth Platform Built Around Personalized, Clinician-Guided GLP-1 Care
13/09/2026
The platform combines online access, individualized treatment, home delivery, and continued patient support in one connected care experience Winter Park, FL, Sept. 12, 2026 (GLOBE NEWSWIRE) -- Zenbody RX has launched [...]
Erica Zarkovich, Chief Market and Partnerships Officer, Named One of Canada’s Most Powerful Women: Top 100
11/09/2026
Toronto, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Erica Zar kovich, Chief Market and Partnerships Officer, has been named one of Canada’s Most Powerful Women: Top 100 by WXN Media in the CN Executive Leaders category [...]

Pages